Over One-Third of Infants Diagnosed With Peanut Allergy May Not Have It, New Study Finds

13 hours ago 3

For years, a childhood peanut allergy diagnosis has felt like an uncompromising lifelong sentence of vigilance, strict avoidance, and persistent anxiety for families. However, groundbreaking pediatric allergy research suggests that conventional diagnostic models may be casting too wide a net. In a landmark clinical investigation published in The Journal of Allergy and Clinical Immunology: In Practice, medical researchers discovered that more than a third of infants thought to be allergic to peanuts were able to safely tolerate them when tested under direct clinical supervision.

Challenging the Standard Allergy Diagnosis

The research emerged from the Allergy Development to an Accelerated Path to Tolerance (ADAPT) Peanut Oral Immunotherapy program, an initiative spearheaded by the Murdoch Children’s Research Institute (MCRI) and the National Allergy Centre of Excellence (NACE) across 10 pediatric public hospitals throughout Australia. The cohort focused on infants under 12 months of age who presented with a documented clinical history of an adverse reaction alongside confirmed sensitization via skin prick tests or elevated peanut-specific blood biomarkers (Ara h 2 specific IgE).

Historically, clinical practice frequently paired a past reaction with a positive biomarker result to assign a permanent peanut allergy label without requiring an oral food challenge (OFC). Because oral challenges involve incremental ingestion of the actual allergen, clinicians and caregivers often deferred them due to safety concerns, clinical time, or resource constraints.

To evaluate baseline eligibility and establish starting dosages for oral immunotherapy (OIT), researchers conducted threshold oral food challenges (TOFCs) with 778 infants who had a median age of 13 months. In escalating increments ranging from 15 milligrams to 1,300 milligrams of peanut protein—roughly equivalent to a teaspoon of peanut butter—the infants were closely monitored by specialized medical staff.

The outcome was striking: 34.8% of infants (271 of 778) experienced a completely negative challenge. Despite having both a prior adverse reaction on record and positive skin or blood sensitization tests, these infants showed no allergic reaction during the supervised challenge, proving they could tolerate peanut protein.

The Critical Role of Supervised Oral Food Challenges

“History and allergy testing alone aren’t enough to diagnose peanut allergy in many infants,” explained Dr. Timothy Brettig, MCRI Population Allergy Group senior research clinician and ADAPT medical lead. “Being able to identify those children early allows them to avoid an unnecessary allergy label and the burden of avoiding peanut.”

For the 34.8% of infants cleared of the allergy, the diagnosis was removed, allowing them to safely incorporate age-appropriate peanut products, such as smooth peanut butter, into their standard diets. Delabeling not only removes intense social and dietary stress for families but also spares children from unnecessary, long-term oral immunotherapy regimens.

Conversely, 65.2% of infants (507 children) did experience an allergic reaction during testing, with a median eliciting threshold of 120 milligrams of peanut protein. Anaphylaxis occurred in 12.0% of those who reacted (61 infants, representing 7.8% of the entire tested cohort). All anaphylactic events were promptly and safely reversed with epinephrine by trained medical staff.

The presence of anaphylaxis underlines why leading researchers emphasize that an oral food challenge must never be attempted at home. These diagnostic procedures must occur inside appropriately staffed and equipped pediatric clinical centers capable of immediate emergency intervention.

Biomarkers Cannot Predict Severity

The research also shed light on the predictive limitations of conventional testing. While infants who experienced allergic reactions generally displayed higher baseline skin prick measurements and higher Ara h 2 specific IgE antibody levels than those who passed, these biomarkers did not reliably forecast the severity of the reaction or the specific threshold of peanut protein required to trigger symptoms.

Every infant presenting with a skin prick test of 12 millimeters or greater, or an Ara h 2 level of at least 5 kUA/L, demonstrated a positive challenge. Yet below those thresholds, biomarkers failed to reliably distinguish between true clinical reactivity and safe tolerance.

For the infants who did show true allergic sensitivity, the food challenge served a dual purpose: it established a precise individual threshold, allowing clinicians to begin oral immunotherapy below the reactive dose. Of the 394 infants who initiated peanut OIT, 97.5% (384 infants) successfully started treatment on their target dosage without issue.

What This Means for Families and Healthcare Systems

According to organizations like Food Allergy Research & Education (FARE), roughly 6.2 million children and adults in the United States live with peanut allergies. While modern dietary guidance encourages early peanut introduction during infancy to reduce allergy development, misdiagnosis remains a major hurdle. When non-allergic infants are mislabeled based solely on ambiguous skin or blood tests, families endure needless anxiety, increased grocery costs, and unnecessary social restrictions.

Accurate clinical confirmation through supervised oral food challenges allows healthcare systems to allocate intensive immunotherapy therapies to children who genuinely require treatment, while freeing tolerant infants from a life of avoidable dietary restrictions.

This article contains affiliate links. We may earn a commission from qualifying purchases.

This article contains affiliate links. We may earn a commission from qualifying purchases.

Originally referenced from healthline.com.

The post Over One-Third of Infants Diagnosed With Peanut Allergy May Not Have It, New Study Finds appeared first on The Hype Magazine.

Read Entire Article